Esperion Therapeutics Stock News

NEW YORK , Dec. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIDI, EDU, LGVN, CCL, and ESPR. Full story available on Benzinga.com

Esperion Therapeutics Inc (NASDAQ: ESPR ) priced its previously announced underwritten public offering of 32.14 million shares and short-term warrants to purchase up to 32.14 million shares at $7/share and accompanying warrant . The short-term warrants have an exercise price of $9.00 per share, are exercisable immediately, and will expire two years following the date of Full story available on Benzinga.com

Esperion Therapeutics Inc (NASDAQ: ESPR) priced its previously announced underwritten public offering of 32.14 million shares and short-term warrants to purchase up to 32.14 million shares at $7/sha

The stock price of Esperion Therapeutics Inc (NASDAQ: ESPR) fell by over 30% pre-market today. This is why it happened.

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

The moving averages on the daily timeframe suggest a bearishness in price, as the 20, 50, 100 and 200 are all in a bearish alignment -- meaning the shorter duration moving averages are below the longer duration averages, implying a stable downward trend. The post Esperion Therapeutics Inc (ESPR): Price Down $-0.11 (-1.41)% Over Past Day, Down $-0.15 (-1.92)% Over Past Hour appeared first on ETF Daily News .

During the last session, Esperion Therapeutics Inc. (NASDAQ:ESPR)s traded shares were 6.98 million, with the beta value of the company hitting 0.88. At the end of the trading day, the stocks price was $7.69, reflecting an intraday loss of -23.25% or -$2.33. The 52-week high for the ESPR share is $39.49, that puts it down How Will Esperion Therapeutics Inc. (NASDAQ: ESPR) Look After It Drops -413.52% From Its Highs? Read More »

Esperion Therapeutics, Inc. (ESPR) with the stream of -22.95% also noticed, India Gerdau S.A. (GGB) encountered a rapid change of 1.55% in the last hour of Wednesdays trading session. Esperion The post Sector Percentage Losers: Esperion Therapeutics, Inc. (NASDAQ:ESPR), Gerdau S.A. (NYSE:GGB) appeared first on Stocks Equity .

Man Group plc cut its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 50.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,778 shares of the biopharmaceutical companys stock after selling 14,248 shares during the quarter. Man Group plcs []

Investors need to pay close attention to Esperion Therapeutics (ESPR) stock based on the movements in the options market lately.

Maverick Capital Ltd. bought a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 44,992 shares of the biopharmaceutical companys stock, valued at approximately $952,000. Several other hedge funds have also bought and sold shares of ESPR. []

Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.

Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q3 2021 Results - Earnings Call Transcript

Esperion continues to struggle to get NEXLETOL and NEXLIZET off the launch pad as COVID-19 headwinds disrupt their commercial efforts. The lackluster launch and relentless cash burn has crushed the sh